Regulatory News:

EOS imaging (Paris:EOSI) (NYSE Euronext, FR0011191766 - EOSI), the pioneer in orthopaedic 2D/3D imaging, today announced the filing of its 2012 Annual Financial Report.

The Annual Financial Report is now available to the public, and has been registered with the Autorité des Marchés Financiers.

The Annual Financial Report is available at the registered office of the company (10 rue Merc?"ur - 75011 Paris) and on the EOS imaging's website at www.eos-imaging.com in the section "Investors / Documentation / Financial Reports".

About EOS imaging:

The EOS imaging group designs, develops and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Group has obtained authorization to market the system in 30 countries, including the United States (FDA), Canada, Australia and the European Union (EU). With an installed base of more than 60 sites and more than 350,000 imaging sessions, EOS® benefits from worldwide recognition and established credibility within the medical community. The Group currently employs 63 people, including an R&D team of 23 engineers, and recorded consolidated revenue of ?9.42 million in 2012. The Group's head office is based in Paris, with 3 international subsidiaries in Cambridge (Massachusetts), Montreal and Germany. For further information, please go to: www.eos-imaging.com.

EOS imaging is listed on Compartment C of the NYSE Euronext Paris
ISIN: FR0011191766 - Ticker: EOSI

Next update: half year 2013 revenues: July 17, 2013 after market close

EOS imaging
Anne Renevot, +33 (0)1 55 25 61 24
CFO
investors@eos-imaging.com
or
The Ruth Group (US)
Press Relations - Lisa Cook, 646-536-7012
lcook@theruthgroup.com
or
NewCap.
Financial communication and investor relations
Sophie Boulila / Pierre Laurent, +33 (0)1 44 71 94 91
eosimaging@newcap.fr
or
ALIZE RP (Europe)
Press Relations
Caroline Carmagnol, +33 (0)1 42 68 86 43 / +33 (0)6 64 18 99 59
caroline@alizerp.com